Developing a Bispecific anti-VEGF/Complement C3 Inhibitor to Treat nAMD & Macular Atrophy
Time: 11:00 am
day: Day One
Details:
- Wet AMD patients with anti-VEGF therapies develop geographic atrophy
- A combination of VEGF and C3 inhibition may result in superior outcome in wet AMD patients
- Novel endpoints are needed to assess the functional benefits of GA therapies
